About Roivant Sciences
Roivant Sciences is a company based in New York (United States) founded in 2014 by Vivek Ramaswamy. Roivant Sciences has raised $1.3 billion across 4 funding rounds from investors including HHS, RTW Investments and SoftBank Vision Fund. The company has 750 employees as of March 31, 2024. Roivant Sciences has completed 2 acquisitions, including Plexcera Therapeutics and Silicon Therapeutics. Roivant Sciences offers products and services including Vants, Immunovant, Priovant, and Pulmovant. Roivant Sciences operates in a competitive market with competitors including Merck, AbbVie, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter New York, United States
- Employees 750 as on 31 Mar, 2024
- Founders Vivek Ramaswamy
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Roivant Sciences Ltd.
-
Annual Revenue
$29.05 M (USD)-11.19as on Mar 31, 2025
-
Net Profit
-$171.98 M (USD)-103.95as on Mar 31, 2025
-
EBITDA
-$1.11 B (USD)-35.86as on Mar 31, 2025
-
Total Equity Funding
$1.3 B (USD)
in 4 rounds
-
Latest Funding Round
$200 M (USD), Private Equity Round
Nov 13, 2018
-
Investors
HHS
& 5 more
-
Employee Count
750
as on Mar 31, 2024
-
Investments & Acquisitions
Plexcera Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Roivant Sciences
Roivant Sciences is a publicly listed company on the NASDAQ with ticker symbol ROIV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Roivant Sciences
Roivant Sciences offers a comprehensive portfolio of products and services, including Vants, Immunovant, Priovant, and Pulmovant.
Platform for creating focused subsidiaries to develop medicines
Subsidiary advancing treatments for autoimmune diseases
Subsidiary targeting severe autoimmune conditions
Subsidiary focused on pulmonary disease treatments
People of Roivant Sciences
Unlock access to complete
Unlock access to complete
Leadership Team
24 people
Finance and Accounting
11 people
Board Team
9 people
Senior Team
9 people
Software Development Team
7 people
Advisor Team
6 people
Human Resources and Administration
6 people
Head Team
5 people
Unlock access to complete
Funding Insights of Roivant Sciences
Roivant Sciences has successfully raised a total of $1.3B across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $200 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Roivant Sciences
Roivant Sciences has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RTW Investments and SoftBank Vision Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
PE firm focused on life science and healthcare companies
|
Locked | Locked | Locked |
Investor details for Roivant Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Roivant Sciences
Roivant Sciences has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Plexcera Therapeutics and Silicon Therapeutics.
Investment portfolio details for Roivant Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of In-Silico Targeted Engineering platform to build in silico models of human drug targets
|
Locked | Locked | 2016 | Locked | |
|
Therapeutics for genetic diseases using recombinant acid ceramidase are developed.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Roivant Sciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Roivant Sciences
Detailed financials for Roivant Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Roivant Sciences Comparisons
Peer comparison for Roivant Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Roivant Sciences
Roivant Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Roivant Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Roivant Sciences
Complete news archive for Roivant Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Roivant Sciences
Roivant Sciences was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Roivant Sciences is headquartered in New York, United States. It is registered at New York, New York, United States.
Matthew Gline is the current CEO of Roivant Sciences.
Roivant Sciences is a funded company, having raised a total of $1.3B across 4 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Roivant Sciences is 750.
Annual revenue of Roivant Sciences is $29.05M as on Mar 31, 2025.
Roivant Sciences is developing therapeutics in disease areas such as neurology, oncology, rare diseases, and endocrinology. Its CNS drug pipeline include Intepirdine, a selective 5-HT6 receptor antagonist for mild-to-moderate Alzheimers disease (phase 3), dementia with Lewy bodies (DLB) (phase 3), gait and balance impairments in dementia (phase 2); Nelotanserin, agonist of the 5-HT2A receptor for visual hallucinations in Lewy body dementia (phase 2), REM behavior disorder (RBD) in DLB (phase 23); RVT-103 and RVT-104 for Alzheimers disease (phase 1) and Lewy body dementia (phase 1). Other drugs in the pipeline include Relugolix for uterine fibroids (phase 3), endometriosis (phase 3) and prostate cancer (phase 3). It is also developing drugs for atopic dermatitis (phase 2), autism (phase 2), female infertility (phase 2) and Farber disease (phase 2).
Roivant Sciences offers Vants, Immunovant, Priovant, and Pulmovant.
Yes, Roivant Sciences is publicly traded on NASDAQ under the ticker symbol ROIV.
Roivant Sciences has made 2 acquisitions, including Plexcera Therapeutics, and Silicon Therapeutics.
Roivant Sciences has 6 investors. Key investors include HHS, RTW Investments, SoftBank Vision Fund, Dexcel Pharma, and Viking Global Investors.
The ticker symbol of Roivant Sciences is ROIV on NASDAQ.